[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
April 26, 2000

Pharmacoeconomic Analyses: Making Them Transparent, Making Them Credible

Author Affiliations

Author Affiliations: Institute for Health Policy Studies, University of California, San Francisco (Drs Rennie and Luft); and JAMA, Chicago, Ill (Dr Rennie).

JAMA. 2000;283(16):2158-2160. doi:10.1001/jama.283.16.2158

The issue of prescription drug benefits is being hotly debated in the United States. We can be sure that cost-conscious insurance organizations, both governmental and commercial, will demand an ever stronger role in deciding which drugs they pay for and include in managed care formularies. Pharmaceutical companies can be expected to continue to fund analyses of the cost-effectiveness of their products, and, as legal and political maneuvering in the United Kingdom, Canada, and Australia has shown, to continue to bring great political and legal pressure on the organizations responsible for deciding the relative merits of their products.1-3 Much of the battle will revolve around measurements of the cost-effectiveness of new drugs.